BIOVF:OTC-Swedish Orphan Biovitrum AB (publ) (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 24.25

Change

0.00 (0.00)%

Market Cap

USD 7.24B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. It operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-29 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

-0.80 (-0.54%)

USD64.76B 37.74 17.60
MKKGY MERCK Kommanditgesellschaft au..

+0.29 (+1.00%)

USD62.86B 37.72 17.60
ESALY Eisai Co., Ltd

-1.28 (-1.39%)

USD26.41B 21.76 0.14
SFOSF Shanghai Fosun Pharmaceutical ..

-0.08 (-1.81%)

USD17.62B 20.84 2.64
SGIOY Shionogi & Co., Ltd

-0.42 (-3.00%)

USD16.74B 15.22 0.08
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
TEVJF Teva Pharmaceutical Industries..

N/A

USD9.49B 904.00 16.09
GNHAF Vifor Pharma AG

N/A

USD8.86B 53.86 15.73
IPSEF Ipsen S.A

N/A

USD8.54B 21.44 46.84
IPSEY Ipsen S.A

N/A

USD8.54B 13.57 46.84

ETFs Containing BIOVF

Symbol Name Weight Mer Price(Change) Market Cap
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

-1.45 (-0.15%)

USD0.03B
ETLI:F L&G Pharma Breakthrou.. 0.00 % 0.75 %

N/A

USD0.03B
EXSE:F iShares STOXX Europe Smal.. 0.00 % 0.20 %

N/A

USD0.39B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.75 %

-0.09 (-0.87%)

USD0.03B
EXSE:XETRA iShares STOXX Europe Smal.. 0.00 % 0.20 %

-0.14 (-0.50%)

USD0.39B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 49.23% 79% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.23% 78% C+ 76% C
Trailing 12 Months  
Capital Gain 42.65% 84% B 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.65% 84% B 76% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.82% N/A N/A 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.82% N/A N/A 43% F
Risk Return Profile  
Volatility (Standard Deviation) 23.63% N/A N/A 66% D
Risk Adjusted Return 7.70% N/A N/A 44% F
Market Capitalization 7.24B 97% A+ 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.87 27% F 37% F
Price/Book Ratio 3.57 29% F 29% F
Price / Cash Flow Ratio 1.99 13% F 31% F
EV/EBITDA 1.39 64% D 60% D-
Management Effectiveness  
Return on Equity 20.05% 93% A 90% A-
Return on Invested Capital 16.89% 78% C+ 79% C+
Return on Assets 8.83% 94% A 94% A
Debt to Equity Ratio 95.34% 13% F 19% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.02 49% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.